News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
byRoshini Claire Anthony
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
22 Apr 2022

Does reducing salt intake impact CV outcomes?
21 Apr 2022
byRoshini Claire Anthony
An intervention aimed at reducing sodium intake in patients with heart failure (HF) does not reduce the risk of emergency department (ED) presentation or hospitalization for cardiovascular (CV) causes or all-cause death, according to results of the SODIUM-HF* trial. However, patients did experience improvements in quality of life (QoL) and New York Heart Association (NYHA) class.
21 Apr 2022






